In a population of 132 patients with HER2 breast cancers, we have found that the Ki67 value, hormonal receptors condition, and Magnetic Resonance Imaging findings, performed after primary systemic therapy, permit the selection of those patients in whom the benefits of neoadjuvant can safely be transferred to surgical extension. This evidence concerns the gene MKI67 and breast carcinoma.